Alterity Therapeutics Limited
corporate_fare Company Profile
Alterity Therapeutics Limited (NASDAQ:ATHE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for ATHE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ATHE spans 6-K, 20-F.
Recent high-impact activity:
- Alterity Holds A$41.3M After A$5.5M Option Proceeds; Phase 3 Start-Up Underway
- Alterity AGM Seeks 25% Placement Capacity, Director Options and Auditor Swap to BDO
- ATH434 Slows MSA Functional Decline by 52% in New Phase 2 Analysis
- FDA Alignment Secured for Phase 3 Design of ATH434 in MSA
- Alterity Therapeutics Prices 8.4M Share Placement at A$0.50, Raising A$4.2M
Financial Snapshot
Short Interest & Short Volume
1.17 days to coverFINRA reported short interest of 38,516 shares in ATHE as of the October 15, 2026 settlement, a 47.5% increase from the prior period — about 1.2 days to cover at its recent average daily volume. On October 30, 2026, 13.4% of ATHE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ATHE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-29.
Option Expiry Notice · Potential Share Issuance
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ATHE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.